Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

Varicella-zoster virus-specific immunity after herpes zoster.

Hayward A, Levin M, Wolf W, Angelova G, Gilden D.

J Infect Dis. 1991 Apr;163(4):873-5.

PMID:
1849165
2.

Vaccination of immunocompetent elderly subjects with a live attenuated Oka strain of varicella zoster virus: a randomized, controlled, dose-response trial.

Trannoy E, Berger R, Holländer G, Bailleux F, Heimendinger P, Vuillier D, Creusvaux H.

Vaccine. 2000 Feb 25;18(16):1700-6.

PMID:
10689152
3.

Use of a live attenuated varicella vaccine to boost varicella-specific immune responses in seropositive people 55 years of age and older: duration of booster effect.

Levin MJ, Barber D, Goldblatt E, Jones M, LaFleur B, Chan C, Stinson D, Zerbe GO, Hayward AR.

J Infect Dis. 1998 Nov;178 Suppl 1:S109-12.

PMID:
9852987
4.

Immune response of elderly individuals to a live attenuated varicella vaccine.

Levin MJ, Murray M, Rotbart HA, Zerbe GO, White CJ, Hayward AR.

J Infect Dis. 1992 Aug;166(2):253-9.

PMID:
1321859
6.
7.
8.

Cell-mediated immunity to varicella-zoster virus.

Arvin AM.

J Infect Dis. 1992 Aug;166 Suppl 1:S35-41. Review.

PMID:
1320649
9.

Immunization of the elderly to boost immunity against varicella-zoster virus (VZV) as assessed by VZV skin test reaction.

Takahashi M, Kamiya H, Asano Y, Shiraki K, Baba K, Otsuka T, Hirota T, Yamanishi K.

Arch Virol Suppl. 2001;(17):161-72. Review.

PMID:
11339545
10.

Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.

Distler E, Schnürer E, Wagner E, von Auer C, Plachter B, Wehler D, Huber C, Kolbe K, Meyer RG, Herr W.

Biol Blood Marrow Transplant. 2008 Dec;14(12):1417-24. doi: 10.1016/j.bbmt.2008.09.004.

11.

Restoration of varicella-zoster virus cell-mediated immune response after varicella booster vaccination.

Berger R, Luescher D, Just M.

Postgrad Med J. 1985;61 Suppl 4:143-5.

PMID:
3014472
12.
13.

Cellular immunity to varicella-zoster virus in patients with major depression.

Irwin M, Costlow C, Williams H, Artin KH, Chan CY, Stinson DL, Levin MJ, Hayward AR, Oxman MN.

J Infect Dis. 1998 Nov;178 Suppl 1:S104-8. Erratum in: J Infect Dis 1999 Mar;179(3):753.

PMID:
9852986
14.

Antibodies against varicella-zoster virus and herpes simplex virus deoxythymidine kinase in heterologous infections.

Källander CF, Torfason EG, Olding-Stenkvist E, Sundqvist VA, Diderholm H, Gronowitz JS.

J Med Virol. 1989 May;28(1):30-7.

PMID:
2542443
15.

Systemic varicella zoster virus reactive effector memory T-cells impaired in the elderly and in kidney transplant recipients.

van Besouw NM, Verjans GM, Zuijderwijk JM, Litjens NH, Osterhaus AD, Weimar W.

J Med Virol. 2012 Dec;84(12):2018-25. doi: 10.1002/jmv.23427.

PMID:
23080511
16.

Altered phenotype and functionality of varicella zoster virus-specific cellular immunity in individuals with active infection.

Schub D, Janssen E, Leyking S, Sester U, Assmann G, Hennes P, Smola S, Vogt T, Rohrer T, Sester M, Schmidt T.

J Infect Dis. 2015 Feb 15;211(4):600-12. doi: 10.1093/infdis/jiu500. Epub 2014 Sep 1.

PMID:
25180236
17.
18.
19.

A dose-response study of a live attenuated varicella-zoster virus (Oka strain) vaccine administered to adults 55 years of age and older.

Berger R, Trannoy E, Holländer G, Bailleux F, Rudin C, Creusvaux H.

J Infect Dis. 1998 Nov;178 Suppl 1:S99-103.

PMID:
9852985
20.

Comparison of a live attenuated and an inactivated varicella vaccine to boost the varicella-specific immune response in seropositive people 55 years of age and older.

Levine MJ, Ellison MC, Zerbe GO, Barber D, Chan C, Stinson D, Jones M, Hayward AR.

Vaccine. 2000 Jun 15;18(25):2915-20.

PMID:
10812235

Supplemental Content

Support Center